Skin-Sights from Maui Derm NP+PA Fall

Welcome to this week's edition of Dermatology Times' LinkedIn newsletter!

This week, Dermatology Times traveled to Nashville, Tennessee, to attend and cover the 2024 Maui Derm NP+PA Fall meeting. Our team spoke with session speakers and expert dermatologists who addressed numerous topics of interest, including rosacea treatment, neoadjuvant treatment for pigmented lesions, blistering diseases, and more. View our comprehensive conference coverage here. If you'd like to keep up with conference pearls and insights as they happen live, be sure to sign up for our e-newsletter.

If you have questions, suggestions, or would like to contribute to a future edition, please contact us via LinkedIn or via email at [email protected].

?? Expert Insights - CONFERENCE EDITION

Explore clinical conference insights from: Sheila Fallon Friedlander, MD; Melodie Young , MSN, ANP-C; Jason Hawkes, MD; Raj Chovatiya, MD, PhD, MSCI ; James Q. Del Rosso, DO ; Julie Harper, MD; Jerry Shapiro, MD; Matthew Zirwas , MD; Donna Culton, MD, PhD; Hensin Tsao , MD, PhD; and Hilary Baldwin, M.D. .

?? Breaking News Brief

LEO Pharma has introduced its 300 mg/2 mL autoinjector of tralokinumab-ldrm (Adbry) for US adults with moderate to severe atopic dermatitis, reducing the number of self-injections by half compared to the previous 150 mg pre-filled syringe. This new option follows FDA approval in June and aims to ease treatment burdens. The initial dosing starts at 600 mg, followed by a 300 mg maintenance dose every 2 weeks, with a monthly option available after 16 weeks for eligible patients.

Organon is acquiring Dermavant Sciences, an Organon company and its tapinarof cream 1% (Vtama), a treatment for plaque psoriasis. The $1.2 billion deal includes a $175 million upfront payment and milestone payments. This acquisition aligns with Organon's focus on enhancing women's health and addressing gender-specific needs in dermatological care.

?? Research Roundup

DermaSensor, Inc. published data showing its DermaSensor device effectively distinguishes between benign and malignant skin lesions. In a study with 155 patients, the device demonstrated a sensitivity of 90%, significantly higher than the 40% achieved by standard care, while maintaining a specificity of 60.7%.

?? Skin In The News

• A recent study assessed the performance of ChatGPT 4.0 on dermatology boards-style practice questions, finding that AI correctly answered 77.3% of the questions, performing better with text-only questions than those with images.
• A recent study indicates that permanent makeup pigments can heighten the risk of allergic contact dermatitis, particularly from inorganic compounds like iron oxides and titanium dioxide.

?? Read more here.

Thank you for reading!